Identification of Metabolic Pathways Involved in the Biotransformation of Tolperisone by Human Microsomal Enzymes
Authors:
- János LeibingerJLJános Leibinger
- Szabolcs SzeberényiSSSzabolcs Szeberényi
- Tı́mEa BorbásTBTı́mEa Borbás
- Sándor FarkasSFSándor Farkas
- Károly TihanyiKTKároly Tihanyi
Open Access
- 1 May 2003
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 31 (5) , 631-636
Abstract
The in vitro metabolism of tolperisone, 1-(4-methyl-phenyl)-2-methyl-3-(1-piperidino)-1-propanone-hydrochloride, a centrally acting muscle relaxant, was examined in human liver microsomes (HLM) and recombinant enzymes. Liquid chromatography-mass spectrometry measurements revealed methyl-hydroxylation (metabolite at m/z 261; M1) as the main metabolic route in HLM, however, metabolites of two mass units greater than the parent compound and the hydroxy-metabolite were also detected (m/z 247 and m/z 263, respectively). The latter was identified as carbonyl-reduced M1, the former was assumed to be the carbonyl-reduced parent compound. Isoform-specific cytochrome P450 (P450) inhibitors, inhibitory antibodies, and experiments with recombinant P450s pointed to CYP2D6 as the prominent enzyme in tolperisone metabolism. CYP2C19, CYP2B6, and CYP1A2 are also involved to a smaller extent. Hydroxymethyl-tolperisone formation was mediated by CYP2D6, CYP2C19, CYP1A2, but not by CYP2B6. Tolperisone competitively inhibited dextromethorphan O-demethylation and bufuralol hydroxylation (Ki = 17 and 30 μM, respectively). Tolperisone inhibited methylp-tolyl sulfide oxidation (Ki = 1200 μM) in recombinant flavin-containing monooxygenase 3 (FMO3) and resulted in a 3-fold (p < 0.01) higher turnover number using rFMO3 than that of control microsomes. Experiments using nonspecific P450 inhibitors—SKF-525A, 1-aminobenzotriazole, 1-benzylimidazole, and anti-NADPH-P450-reductase antibodies—resulted in 61, 47, 49, and 43% inhibition of intrinsic clearance in HLM, respectively, whereas hydroxymethyl-metabolite formation was inhibited completely by nonspecific chemical inhibitors and by 80% with antibodies. Therefore, it was concluded that tolperisone undergoes P450-dependent and P450-independent microsomal biotransformations to the same extent. On the basis of metabolites formed and indirect evidences of inhibition studies, a considerable involvement of a microsomal reductase is assumed.Keywords
This publication has 29 references indexed in Scilit:
- A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomesArchives of Toxicology, 1996
- Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9Xenobiotica, 1995
- Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in HumansBiochemistry, 1994
- Role of flavin-dependent monooxygenases and cytochrome P450 enzymes in the sulfoxidation of S-methyl N,N-diethylthiolcarbamateBiochemical Pharmacology, 1993
- Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafyllineChemical Research in Toxicology, 1993
- Tolbutamide hydroxylation by human liver microsomesBiochemical Pharmacology, 1988
- High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liverAnalytical Biochemistry, 1987
- Gas—liquid chromatographic method for the determination of tolperisone in human plasma: pharmacokinetic and comparative bioavailability studiesJournal of Pharmaceutical and Biomedical Analysis, 1987
- Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activitiesBiochemical Pharmacology, 1985
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984